Кристи Фанк - Грудь. Руководство пользователя [litres]

U. Veronesi et al., “Effect of Menstrual Phase on Surgical Treatment of Breast Cancer,” The Lancet 343 (1994): 1544–1546; R. A. Badwe, I. Mittra, and R. Havaldar, “Timing of Surgery during the Menstrual Cycle and Prognosis of Breast Cancer,” Journal of Biosciences 25, no. 1 (2000): 113–120; I. S. Fentiman, “Timing of Surgery for Breast Cancer,” International Journal of Clinical Practice 56, no. 3 (2002): 188–190; D. Coradini et al., “Fluctuation of Intratumor Biological Variables as a Function of Menstrual Timing of Surgery for Breast Cancer in Premenopausal Patients,” Annals of Oncology 14, no. 6 (2003): 962–964; Z. Saad et al., “Timing of Surgery Influences Survival in Receptor-Negative as Well as Receptor-Positive Breast Cancer,” European Journal of Cancer 30A, no. 9 (1994): 1348–1352; R. T. Senie et al., “Timing of Breast Cancer Excision during the Menstrual Cycle Influences Duration of Disease-Free Survival,” Annals of Internal Medicine 115, no. 5 (1991): 337–342.

A. Goldhirsch et al., “Timing Breast Cancer Surgery,” The Lancet 338 (1991): 691–692; B. Nathan et al., “Timing of Surgery for Breast Cancer in Relation to the Menstrual Cycle and Survival of Premenopausal Women,” British Journal of Surgery 80 (1993): 43; P. Pujol et al., “A Prospective Prognostic Study of the Hormonal Milieu at the Time of Surgery in Premenopausal Breast Carcinoma,” Cancer 91, no. 10 (2001): 1854–1861; Y. Nomura et al., “Lack of Correlation between Timing of Surgery in Relation to the Menstrual Cycle and Prognosis of Premenopausal Patients with Early Breast Cancer,” European Journal of Cancer 35, no. 9 (1999): 1326–1330; Y. Takeda et al., “Does the Timing of Surgery for Breast Cancer in Relation to the Menstrual Cycle or Geomagnetic Activity Affect Prognoses of Premenopausal Patients?” Biomedicine and Pharmacotherapy 57, no. 1 (2003): 96s–103s; A. Mangia et al., “Timing of Breast Cancer Surgery within the Menstrual Cycle: Tumor Proliferative Activity, Receptor Status and Short-Term Clinical Outcome,” Journal of Experimental and Clinical Cancer Research 17, no. 3 (1998): 317–323; G. Mondini et al., “Timing of Surgery Related to Menstrual Cycle and Prognosis of Premenopausal Women with Breast Cancer,” AntiCancer Research 17, no. 1B (1997): 787–790; K. Holli, J. Isola, and M. Hakama, “Prognostic Effect of Timing of Operation in Relation to Menstrual Phase of Breast Cancer Patient – Fact or Fallacy,” British Journal of Cancer 71, no. 1 (1995): 124–127; N. Kroman et al., “Timing of Surgery in Relation to Menstrual Cycle Does Not Predict the Prognosis in Primary Breast Cancer,” European Journal of Surgical Oncology 20, no. 4 (1994): 430–435; M. F. Gnant et al., “Breast Cancer and Timing of Surgery during Menstrual Cycle: a 5-Year Analysis of 385 Premenopausal Women,” International Journal of Cancer 52, no. 4 (1992): 707–712.

W. L. McGuire, “The Optimal Timing of Mastectomy: Low Tide or High Tide,” Annals of Internal Medicine 115 (1991): 401–403.

H. Thorpe et al., “Timing of Breast Cancer Surgery in Relation to Menstrual Cycle Phase: No Effect on 3-Year Prognosis: The ITS Study,” British Journal of Cancer 98, no. 1 (2008): 39–44; C. S. Grant et al., “Menstrual Cycle and Surgical Treatment of Breast Cancer: Findings from the NCCTG N9431 Study,” Journal of Clinical Oncology 27, no. 22 (2009): 3620–3626; P. Pujol et al., “A Prospective Prognostic Study of the Hormonal Milieu at the Time of Surgery in Premenopausal Breast Carcinoma,” Cancer 91 (2001): 1854–1861.

B. Fisher et al., “Reanalysis and Results after 12 Years of Follow-Up in a Randomized Clinical Trial Comparing Total Mastectomy with Lumpectomy with or without Irradiation in the Treatment of Breast Cancer,” New England Journal of Medicine 333 (1995): 1456–1461.

R. Holland et al., “Histologic Multifocality of Tis, T1–2 Breast Carcinomas: Implications for Clinical Trials of Breast-Conserving Surgery,” Cancer 56 (1985): 979–990.

M. Clarke et al., “Effects of Radiotherapy and of Differences in the Extent of Surgery for Early Breast Cancer on Local Recurrence and 15-Year Survival: An Overview of the Randomised Trials,” The Lancet 366 (2005): 2087–2106.

J. Hastings et al., “Risk Factors for Locoregional Recurrence after Mastectomy in Stage T1 N0 Breast Cancer,” American Journal of Clinical Oncology 37, no. 5 (2014): 486–491.

A. McBride et al., “Locoregional Recurrence Risk for Patients with T1, 2 Breast Cancer with 1–3 Positive Lymph Nodes Treated with Mastectomy and Systemic Treatment,” International Journal of Radiation Oncology * Biology * Physics 89, no. 2 (2014): 392–398.

G. Jacobson, et al., “Randomized Trial of Pentoxifylline and Vitamin E vs Standard Follow-Up after Breast Irradiation to Prevent Breast Fibrosis, Evaluated by Tissue Compliance Meter,” International Journal of Radiation Oncology* Biology* Physics 85, no. 3 (2013): 604–608; T. B. Chiao and A. J. Lee, “Role of Pentoxifylline and Vitamin E in Attenuation of Radiation-Induced Fibrosis,” Annals of Pharmacotherapy 39, no. 3 (2005): 516–522.

T. J. Whelan et al., “Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer,” New England Journal of Medicine 362, no. 6 (2010): 513–520.

T. D. Smile et al., “Accelerated Partial-Breast Irradiation: An Emerging Standard of Care,” Applied Radiation Oncology , http://appliedradiationoncology.com/articles/accelerated-partial-breast-irradiation-an-emerging-standard-of-care.

U. Veronesi et al., “Radiotherapy after Breast-Conserving Surgery in Small Breast Carcinoma: Long-Term Results of a Randomized Trial,” Annals of Oncology 12 (2001): 997–1003.

F. Sedlmayer, F. Zehentmayr, and G. Fastner, “Partial Breast Re-irradiation for Local Recurrence of Breast Carcinoma: Benefit and Long Term Side Effects,” The Breast 22, no. 2 (August 2013): S141–S146.

J. S. Vaidya et al., “Targeted Intraoperative Radiotherapy (TARGIT): An Innovative Approach to Partial-Breast Irradiation,” Seminars in Radiation Oncology 15, no. 2 (April 2005): 84–91; U. Veronesi et al., “Intraoperative Radiotherapy Versus External Beam Radiotherapy for Early Breast Cancer (ELIOT): A Randomised Controlled Equivalence Trial,” The Lancet Oncology 14, no. 13 (December 2013): 1269–1277.

C. Shah, J. Wobb, and A. Khan, “Intraoperative Radiation Therapy in Breast Cancer: Still Not Ready for Prime Time,” Annals of Surgical Oncology 23, no. 6 (2016): 1796–1798.

American Cancer Society, Global Cancer Facts and Figures , Third Edition (Atlanta, GA: American Cancer Society, 2015), https://www.cancer.org/content/dam/cancerorg/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/globalcancer-facts-and-figures-3rd-edition.pdf.

M. Clarke et al., “Effects of Radiotherapy and of Differences in the Extent of Surgery for Early Breast Cancer on Local Recurrence and 15-Year Survival: An Overview of the Randomised Trials,” The Lancet 366, no. 9503 (December 2005): 2087–2106.